Cancer Diagnostics Market Share ,Competitive , Strategies and Segment ,Forecast to 2034
Global Cancer Diagnostics Market Size- By Product, By Type, By Application, By End-User, By Test Type, By Coverage- Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jul-2025 | Report ID: HLCA25195 | Pages: 1 - 244 | Formats*: |
| Category : Healthcare | |||
Cancer Diagnostics Market Introduction and Overview
According to SPER Market Research, the Global Cancer Diagnostics Market is estimated to reach USD 204.98 billion by 2034 with a CAGR of 6.43%.
The report includes an in-depth analysis of the Global Cancer Diagnostics Market, including market size and trends, product mix, Applications, and supplier analysis. The Global Cancer Diagnostics Market was valued at USD 109.92 billion in 2024 and is estimated to grow at a CAGR 6.43% from 2025 to 2034. The market for cancer diagnostics is one area of the healthcare sector that is expanding quickly due to the rising incidence of cancer worldwide and the need for precise and early detection. Imaging systems, biopsy tools, molecular diagnostics, and laboratory testing are just a few of the many goods and services it includes. The scene is changing due to technological developments like AI in imaging, liquid biopsies, and genomic profiling, which allow for earlier detection and more individualized treatment. Government initiatives, enhanced screening programs, and growing healthcare awareness also have an impact on the industry. The need for efficient diagnostic tools keeps growing as the number of cancer patients worldwide rises.
By Product Insights
The strong demand for test kits, reagents, and related materials used in routine cancer screening and diagnosis is reflected in the consumables segment's highest share of the cancer diagnostics market in 2024. The development of efficient monoclonal antibody-based assays for identifying antigens and small compounds produced by malignant cells, along with improvements in imaging diagnostic techniques, are anticipated to greatly improve diagnostic capabilities. Over the next few years, the services segment is anticipated to expand at a noteworthy rate. This includes software interfaces for using diagnostic tools, performing analyses, and deciphering findings.
By Type Insights
Increased testing requirements during the COVID-19 pandemic and the broad use of IVD techniques propelled the in vitro diagnostics (IVD) segment to the top of the cancer diagnostics market in 2024. Laboratory Diagnostic Tests (LDTs) are expected to grow rapidly, as they enable swift integration of new clinical insights for personalized treatments.
By Application Insights
The breast cancer industry led the cancer diagnostics market in 2024, driven by rising research and development in advanced screening techniques to enhance early detection and results. Certain biomarkers have been found to be useful for breast cancer screening because they provide both sensitivity and specificity. The section pertaining to colorectal cancer is anticipated to expand at the quickest rate in the next few years. In order to improve patient survival rates and quality of life, early diagnosis is essential.
By End User Insights
In 2024, the laboratories segment led the cancer diagnostics market, driven by the growing number of diagnostic tests and the availability of advanced resources to support high-throughput testing. Increased awareness of personalized medicine, ongoing technological advancements, and the demand for cost-effective diagnostic services are contributing to the strong growth of this segment. Meanwhile, the "others" segment which includes home-based testing is projected to grow at the fastest pace during the forecast period. This growth is fueled by the rising adoption of home-based and tech-enabled diagnostic solutions.
By Test Type Insights
In 2024, the others category led the market for cancer diagnostics. Finding the inherited risk of breast and ovarian cancers can be aided by comparing panel-based tests to BRCA1/2 genetic testing. Other cancers for which panel-based testing has a higher clinical utility and yield because of hereditary risk include colon cancer and pheochromocytoma-paraganglioma.
Biopsy is predicted to expand at the fastest rate during the projected period because of the test's many advantages, such as early detection. The aggressiveness of the malignancy and its propensity to spread to other organs are also assessed by biopsy.
By Coverage Insights
The public insurance category dominated the cancer diagnostics market in 2024 and is anticipated to increase at the quickest compound annual growth rate (CAGR) throughout the course of the forecast period. Cancer diagnostics are becoming a higher priority for governments and public health organizations in their healthcare programs in order to facilitate early detection, precise diagnosis, and efficient treatment planning.
The growth of private insurance is anticipated to be substantial in the upcoming years. Private insurance dominates the healthcare system in the United States, with major providers like UnitedHealthcare, Anthem, Aetna (CVS Health), and Cigna providing full coverage for cancer diagnostics.
Regional Insights
The rising cancer prevalence in the US and Canada, along with the increasing efforts of medical device companies to deliver advanced diagnostic technologies for early tumor detection, caused North America to lead the global market for cancer diagnostics in 2024. Strong healthcare facilities, ongoing research, and supportive regulations all help the area. Regular product releases are another important factor in the growth of the market.
Market Competitive Landscape
Leading players in the cancer diagnostics market are focusing on R&D, product innovation, strategic collaborations, and acquisitions to strengthen their global presence. Emphasis on early detection, personalized diagnostics, and cost-effective solutions is vital to remain competitive in this evolving sector. Some of the key market players are Abbott, BD, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic, Inc, Illumina, Inc, Koninklijke Philips N.V (Philips), QIAGEN, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc.
Recent Developments:
In December 2024, Guardant Health, Inc. and Boehringer Ingelheim formed a collaboration to get regulatory clearance and advance the Guardant360 CDx liquid biopsy's commercialization. A novel covalent tyrosine kinase inhibitor (TKI) called zongertinib will be utilized in this collaboration as a companion diagnostic (CDx) in liquid biopsy. It targets HER2 specifically while decreasing its impact on the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC).
In November 2024, To further the development of precision medicine, Danaher Corporation announced the creation of two new Centers of Innovation in Diagnostics. The first center, which will be a hub for cooperative research with top academic and pharmaceutical institutions, is set to open in July in Newcastle, UK. Leica Biosystems, a Danaher subsidiary, is hosting this facility, which will be Danaher's first CLIA CAP* lab.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By Type, By Application, By End User, By Test Type, By Coverage |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Abbott, BD, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic, Inc, Illumina, Inc, Koninklijke Philips N.V (Philips), QIAGEN, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc. |
Key Topics Covered in the Report
- Global Cancer Diagnostics Market Size (FY’2021-FY’2034)
- Overview of Global Cancer Diagnostics Market
- Segmentation of Global Cancer Diagnostics Market By Product (Consumables, Instruments, Services)
- Segmentation of Global Cancer Diagnostics Market By Type (IVD, LDT, Imaging)
- Segmentation of Global Cancer Diagnostics Market By Application (Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Ovarian Cancer, Others)
- Segmentation of Global Cancer Diagnostics Market By End User (Hospitals, Laboratories, Others)
- Segmentation of Global Cancer Diagnostics Market By Test Type (Biopsy, Others)
- Segmentation of Global Cancer Diagnostics Market By Coverage (Public Insurance, Private Insurance)
- Statistical Snap of Global Cancer Diagnostics Market
- Expansion Analysis of Global Cancer Diagnostics Market
- Problems and Obstacles in Global Cancer Diagnostics Market
- Competitive Landscape in the Global Cancer Diagnostics Market
- Details on Current Investment in Global Cancer Diagnostics Market
- Competitive Analysis of Global Cancer Diagnostics Market
- Prominent Players in the Global Cancer Diagnostics Market
- SWOT Analysis of Global Cancer Diagnostics Market
- Global Cancer Diagnostics Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPER’s internal database2.1.4.Premium insight from KOL’s
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats5.2.PESTEL Analysis5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape5.3.PORTERs Five Forces5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Cancer Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cancer Diagnostics Market
7.Global Cancer Diagnostics Market, By Product (USD Million) 2021-2034
7.1.Instruments7.1.1.Pathology-based Instruments7.1.1.1.Slide Staining Systems7.1.1.2.Tissue Processing Systems7.1.1.3.Cell Processors7.1.1.4.PCR Instruments7.1.1.5.NGS Instruments7.1.1.6.Microarrays7.1.1.7.Other Pathology-based Instruments7.1.2.Imaging Instruments7.1.3.Others7.2.Consumables7.2.1.Antibodies7.2.2.Kits & reagents7.2.3.Probes7.2.4.Others7.3.Services
8.Global Cancer Diagnostics Market, By Type (USD Million) 2021-2034
8.1. IVD8.1.1.By Type8.1.1.1.Diagnosis8.1.1.2.Early Detection8.1.1.3.Therapy Selection8.1.1.4.Monitoring8.1.2.By Technology8.1.2.1.Polymerase Chain Reaction (PCR)8.1.2.2.In Situ Hybridization (ISH)8.1.2.3.Immunohistochemistry (IHC)8.1.2.4.Next-generation Sequencing (NGS)8.1.2.5.Microarrays8.1.2.6.Flow Cytometry8.1.2.7.Immunoassays8.1.2.8.Other IVD Testing Technologies8.2.LDT8.3.Imaging8.3.1.Magnetic Resonance Imaging (MRI)8.3.2.Computed Tomography (CT)8.3.3.Positron Emission Tomography (PET)8.3.4.Mammography8.3.5.Ultrasound8.3.6.Others
9.Global Cancer Diagnostics Market, By Application (USD Million) 2021-2034
9.1.Breast Cancer9.2.Colorectal Cancer9.3.Cervical Cancer9.4.Lung Cancer9.5.Prostate Cancer9.6.Skin Cancer9.7.Blood Cancer9.8.Kidney Cancer9.9.Liver Cancer9.10.Pancreatic Cancer9.11.Ovarian Cancer9.12.Others
10.Global Cancer Diagnostics Market, By End User (USD Million) 2021-2034
10.1.Hospitals10.2.Laboratories10.3.Others
11.Global Cancer Diagnostics Market, By Test Type (USD Million) 2021-203
11.1.Biopsy
11.1.1.Fine-needle Aspiration11.1.2.Core Biopsy11.1.3.Surgical Biopsy11.1.4.Skin Biopsy /Punch Biopsy11.1.5.Others
11.2.Others
12.Global Cancer Diagnostics Market, By Coverage (USD Million) 2021-2034
12.1.Public Insurance12.2.Private Insurance
13.Global Cancer Diagnostics Market, (USD Million) 2021-2034
13.1.Global Cancer Diagnostics Market Size and Market Share
14.Global Cancer Diagnostics Market, By Region, (USD Million) 2021-2034
14.1.Asia-Pacific14.1.1.Australia14.1.2.China14.1.3.India14.1.4.Japan14.1.5.South Korea14.1.6.Rest of Asia-Pacific14.2.Europe14.2.1.France14.2.2.Germany14.2.3.Italy14.2.4.Spain14.2.5.United Kingdom14.2.6.Rest of Europe14.3.Middle East and Africa14.3.1.Kingdom of Saudi Arabia14.3.2.United Arab Emirates14.3.3.Qatar14.3.4.South Africa14.3.5.Egypt14.3.6.Morocco14.3.7.Nigeria14.3.8.Rest of Middle-East and Africa14.4.North America14.4.1.Canada14.4.2.Mexico14.4.3.United States14.5.Latin America14.5.1.Argentina14.5.2.Brazil14.5.3.Rest of Latin America
15.Company Profile
15.1.Abbott15.1.1.Company details15.1.2.Financial outlook15.1.3.Product summary15.1.4.Recent developments15.2.BD15.2.1.Company details15.2.2.Financial outlook15.2.3.Product summary15.2.4.Recent developments15.3.F. Hoffmann-La Roche Ltd15.3.1.Company details15.3.2.Financial outlook15.3.3.Product summary15.3.4.Recent developments15.4.GE Healthcare15.4.1.Company details15.4.2.Financial outlook15.4.3.Product summary15.4.4.Recent developments15.5.Hologic, Inc15.5.1.Company details15.5.2.Financial outlook15.5.3.Product summary15.5.4.Recent developments15.6.Illumina, Inc15.6.1.Company details15.6.2.Financial outlook15.6.3.Product summary15.6.4.Recent developments15.7.Koninklijke Philips N.V. (Philips)15.7.1.Company details15.7.2.Financial outlook15.7.3.Product summary15.7.4.Recent developments15.8.QIAGEN15.8.1.Company details15.8.2.Financial outlook15.8.3.Product summary15.8.4.Recent developments15.9.Siemens Healthcare GmbH15.9.1.Company details15.9.2.Financial outlook15.9.3.Product summary15.9.4.Recent developments15.10.Thermo Fisher Scientific, Inc15.10.1.Company details15.10.2.Financial outlook15.10.3.Product summary15.10.4.Recent developments15.11.Others
16.Conclusion
17.List of Abbreviations
18.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Cancer Diagnostics Market is projected to reach USD 204.98 by 2034, growing at a CAGR of 6.43% during the forecast period.
Cancer Diagnostics Market size from 2025. The Market is expected to reach USD 204.98 by 2034, at a CAGR of 6.43% during the forecast period.
Cancer Diagnostics Market CAGR of 6.43% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Cancer Diagnostics Market size is USD 204.98 from 2025 to 2034.
"Cancer Diagnostics Market covered By Product, By Type, By Application, By End User, By Test Type, By Covera"
The North America is anticipated to have the highest Market share in the Cancer Diagnostics Market .
"
Abbott, BD, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic, Inc, Illumina, Inc, Koninklijke Philips N.V (Philips), QIAGEN, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc.
"
"
The report includes an in-depth analysis of the Global Cancer Diagnostics Market, including market size and trends, product mix, Applications, and supplier analysis."
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
